Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | LYN | P07948 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.49 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | TEK | Q02763 | 1/20 | 0.49 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.46 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.46 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | PRKDC | P78527 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31439285 | 1.00 | MTOR (0.50) | MTORPIK3CALCKLYNSRC | |
| SCHEMBL1083272 | 0.87 | MTOR (0.51) | MTORPIK3CALCKLYNSRC | |
| SCHEMBL16730908 | 0.85 | MTOR (0.53) | MTORPIK3CALCKLYNSRC | |
| SCHEMBL18998180 | 0.84 | GABRA1 (0.54) | FLT3ATMATRCYP1A2KDM4E | |
| SCHEMBL16719257 | 0.84 | MTOR (0.52) | MTORPIK3CALCKLYNSRC | |
| SCHEMBL16719219 | 0.84 | MTOR (0.57) | MTORPIK3CALCKLYNSRC | |
| SCHEMBL18068262 | 0.84 | MTOR (0.56) | MTORPIK3CALCKLYNSRC | |
| SCHEMBL1074861 | 0.84 | KDM4E (0.46) | HTTKDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL16730785 | 0.83 | MTOR (0.62) | MTORPIK3CALCKLYNSRC | |
| SCHEMBL16719214 | 0.83 | MTOR (0.56) | MTORPIK3CALCKLYNSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3169687-B1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2019-01-02 | — | — | EP | disclosed |
| US-10112945-B2 | Fused quinoline compunds as PI3K, mTOR inhibitors | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2018-10-30 | — | — | US | disclosed |
| WO-2018071836-A1 | COMPOUNDS AND METHOD FOR BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2018-04-19 | — | — | WO | disclosed |
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS NANJING LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| EP-3169687-A2 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | ADVENCHEN PHARMACEUTICALS, NANJING LTD. (CN) | 2017-05-24 | — | — | EP | disclosed |
| US-20160264570-A1 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | LOYOLA UNIVERSITY OF CHICAGO | 2016-09-15 | — | — | US | disclosed |
| US-20160264570-A1 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | LOYOLA UNIVERSITY OF CHICAGO | 2016-09-15 | — | — | US | disclosed |
| US-20160264570-A1 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | LOYOLA UNIVERSITY OF CHICAGO | 2016-09-15 | — | — | US | disclosed |
| WO-2016010869-A2 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | Advenchen Pharmaceuticals, LLC (US) | 2016-01-21 | — | — | WO | disclosed |
| WO-2015073804-A2 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073804-A2 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264570-A1 | METHOD OF BLOCKING TRANSMISSION OF MALARIAL PARASITE | PLK1, TUBA1C, PPT1 | MTOR 320/4885PIK3CA 1958/4885LCK 882/4885 |
| US-11753408-B2 | Compounds and method for blocking transmission of malarial parasite | PLK1, HSP90B1, CEP170 | MTOR 91/4885PIK3CA 1615/4885LCK 887/4885 |
| US-20170174687-A1 | FUSED QUINOLINE COMPUNDS AS PI3K, mTOR INHIBITORS | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3CA 3/4885LCK 891/4885 |
| US-10112945-B2 | Fused quinoline compunds as PI3K, mTOR inhibitors | MTOR, RICTOR, PIK3CA | MTOR 1/4885PIK3CA 3/4885LCK 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.